All In Biotech

Drug Trial Radar · NCT05561751

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

28

Actual

Start

Feb 13, 2023

Primary completion

Sep 30, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
GPCR Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms: * GPC-100 in combination with propranolol; or * GPC-100 in combination with propranolol and G-CSF. To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian Optimal Phase II (BOP2) design to enroll patients for each arm. All patients will receive via IV 3.14 mg/kg GPC-100 (Burixafor) at least 2 hours prior to leukapheresis sessions from Days 7-8 (Days 9-11 optional) and 30 mg propranolol (3 x 10 mg tablets) twice daily at 8:30 AM (+/- 1 hr) and 4:00 PM (+/- 1 hr) local time from Days 1 to 8 (and on Days 9-11, if applicable). Patients will administer the first dose of propranolol onsite on Day 1. Patients will be provided with doses of propranolol for self-administration at time points when they are not otherwise required to be onsite. Sites should contact patients via telephone to confirm propranolol administration for doses administered outside of clinic.

Conditions

  • Multiple Myeloma

Interventions

  • GPC-100Drug

    GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min

  • PropranololDrug

    propranolol

  • G-CSFDrug

    G-CSF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants That Achieve >=2 x 10^6 CD34+ Cells/kg in 2 Leukapheresis SessionsTime frame: First two leukapheresis sessions (study days 7 and 8)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD) - Moores Cancer Center

    La Jolla, California

  • University of Florida (UF) - Shands Cancer Center

    Gainesville, Florida

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana

  • University of Massachusetts

    Worcester, Massachusetts

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • John Theurer Cancer Center At Hackensack UMC

    Hackensack, New Jersey

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Commonwealth University - Massey Cancer Center

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.